The study results were announced Wednesday in an online publication of the journal Nature. If validated by further studies, the discovery could help drug researchers tailor medications to individual patients.
Lilly scientists in Indianapolis and Singapore teamed up with researchers from the Phoenix-based Translational Genomics Research Institute. They found a recurring mutation in a gene known as AKT1 in tumor samples from patients with cancer in their breasts, ovaries or colon.
The institute's director and the study's lead author, John Carpten, said, "This discovery adds to the short but growing list of molecular features that may help guide both current and future cancer drug development."